CLINICAL TRIALS PROFILE FOR ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
✉ Email this page to a colleague
All Clinical Trials for Estradiol; Norethindrone Acetate; Relugolix
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03049735 ↗ | LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Completed | Myovant Sciences GmbH | Phase 3 | 2017-04-26 | The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids. |
| NCT03103087 ↗ | LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Completed | Myovant Sciences GmbH | Phase 3 | 2017-06-14 | The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids. |
| NCT03204318 ↗ | SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain | Completed | Myovant Sciences GmbH | Phase 3 | 2017-12-07 | The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain. |
| NCT03204331 ↗ | SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain | Completed | Myovant Sciences GmbH | Phase 3 | 2017-11-01 | The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain. |
| NCT03412890 ↗ | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Completed | Myovant Sciences GmbH | Phase 3 | 2017-10-19 | The purpose of this study is to determine the long-term efficacy and safety of relugolix 40 milligrams (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for 28 weeks on heavy menstrual bleeding associated with uterine fibroids in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3001 or MVT-601-3002). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Estradiol; Norethindrone Acetate; Relugolix
Condition Name
Clinical Trial Locations for Estradiol; Norethindrone Acetate; Relugolix
Trials by Country
Clinical Trial Progress for Estradiol; Norethindrone Acetate; Relugolix
Clinical Trial Phase
Clinical Trial Sponsors for Estradiol; Norethindrone Acetate; Relugolix
Sponsor Name
